Basal cell carcinoma

The PBS subsidises vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Treatment with vismodegib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with metastatic or locally advanced basal cell carcinoma.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing vismodegib.

Applications

Initial treatment

All initial authority approval applications to prescribe vismodegib for the treatment of basal cell carcinoma must be made in writing:

All applications must include a completed:

The patient cannot receive more than 16 weeks of treatment under this restriction.

Continuing treatment

All initial authority approval applications to prescribe vismodegib for the treatment of basal cell carcinoma must be made in writing:

All applications must include a completed:

The patient cannot receive more than 16 weeks of treatment under this restriction.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 27 August 2017